Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer

Author(s): Jakub Kollar, Vladimir Frecer

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 11 , 2015

Become EABM
Become Reviewer
Call for Editor


Histone deacetylases (HDACs), which act on acetylated histones and/or other non-histone protein substrates, represent validated epigenetic targets for the treatment of cancer and other human diseases. The inhibition of HDAC activity was shown to induce cell cycle arrest, differentiation, apoptosis as well as a decrease in proliferation, angiogenesis, migration, and cell resistance to chemotherapy. Targeting single HDAC isoforms with selective inhibitors will help to reveal the role of individual HDACs in cancer development or uncover further biological consequences of protein acetylation. This review focuses on conventional zinc-containing HDACs. In its first part, the biological role of individual HDACs in various types of cancer is summarized. In the second part, promising HDAC inhibitors showing activity both in enzymatic and cell-based assays are surveyed with an emphasis on the inhibitors selective to the individual HDACs.

Keywords: Epigenetic regulation and cancer, histone deacetylases (HDACs), HDAC inhibitors as anticancer agents, isoform selective HDAC inhibitors, role of HDAC isoforms in cancer.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [1472 - 1502]
Pages: 31
DOI: 10.2174/1381612820666141110164604
Price: $65

Article Metrics

PDF: 56